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Risk factors for hearing loss in children: a
systematic literature review and meta-
analysis protocol
Bénédicte Vos1,2,3, Dorie Noll1,2, Marie Pigeon4, Marlene Bagatto5 and Elizabeth M. Fitzpatrick1,2*
Abstract
Background: Hearing loss in newborns and children is a public health concern, due to high prevalence and
negative effects on their development. Early detection and intervention of childhood hearing loss may mitigate
these negative effects. Population-based newborn hearing screening programs have been established worldwide to
identify children at risk for congenital hearing loss and to follow children at risk for late onset or progressive
hearing loss. This article presents the protocol for a systematic review that aims to review the risk factors associated
with permanent hearing loss in children, including congenital, early, or late onset. Risk factors associated with
progressive hearing loss will be investigated as a secondary aim.
Methods: Scientific literature from the following databases will be investigated: MEDLINE, Ovid MEDLINE(R) Daily
and Ovid MEDLINE(R), Embase, and CINAHL. The primary outcome is a permanent bilateral or unilateral hearing loss
with congenital onset or onset during childhood (birth to 18 years). The secondary outcome is progressive hearing
loss. Studies must report data on risk factors associated with permanent hearing loss; risk factors may be present at
birth or later and result in immediate or delayed hearing loss. Randomized controlled trials, quasi-experimental
studies, nonrandomized comparative and non-comparative studies, and case series will be included. The risk of bias
will be assessed using the Qualitative Assessment Tool for Quantitative Studies (McMaster University). If aggregation
of data is possible for a subsection of studies, we will pool data using meta-analysis techniques. If aggregation of
data is not possible, a qualitative synthesis will be presented. We will assess the quality and strength of the overall
body of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). The
systematic review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
recommendations.
Discussion: The resulting information will inform the update of a provincial audiological surveillance protocol for
the Ontario Infant Hearing Program and will be applicable to early hearing detection and intervention (EHDI)
programs worldwide.
Systematic review registration: We have registered the protocol in the International Prospective Register of
Systematic Reviews (PROSPERO), registration number CRD42018104121.
Keywords: Hearing loss, Congenital hearing loss, Late onset hearing loss, Acquired hearing loss, Progressive hearing
loss, Risk factor, Surveillance, Newborn, Children
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Background
Permanent hearing loss affects at least 1 to 2 per 1000
children at birth and has severe consequences for their
development [1–3]. The negative consequences for lan-
guage, cognitive, and social-emotional skills are particu-
larly important when diagnosis is delayed for children
with hearing loss, which delays access to early interven-
tion programs [4–7]. There is good evidence that univer-
sal newborn hearing screening (UNHS) programs
achieve early identification [8, 9]. When UNHS pro-
grams are implemented as part of a comprehensive early
hearing detection and intervention program (EHDI),
children with congenital and early onset hearing loss are
diagnosed early and supported to develop language in
their first months of life [3, 10].
In addition to screening newborns for hearing loss, there
is a need to monitor children who are at risk of developing
hearing loss after the neonatal period [11–13]. Prior to the
population-based screening, it was difficult to identify
whether hearing loss occurred congenitally, neonatally, or
during early childhood beyond the neonatal period. Studies
suggest that the prevalence of permanent hearing loss rises
during childhood and that hearing loss occurs sometime
after infancy in up to 25–50% of affected children [14–16].
Almost half of the children with hearing loss will experi-
ence deterioration in hearing during childhood [17, 18].
Children at risk for late onset hearing loss need to be
closely monitored, even after passing a screening test, to
ensure identification as early as possible and to avoid de-
lays in treatment, unnecessary costs to the healthcare
system, and additional parental stress [19, 20]. It is also
important to monitor children with early onset hearing
loss who are at risk for further deterioration in hearing
(progressive hearing loss), so that appropriate interven-
tion may be initiated in a timely manner. Surveillance
programs are thus recommended as part of a compre-
hensive EHDI program but not universally applied [21,
22]. They aim to identify children at risk for late onset
or progressive hearing loss and have been implemented
in some UNHS or EHDI programs [11, 23, 24]. However,
the effectiveness of these programs is not well estab-
lished [25].
In 2007, the Joint Committee on Infant Hearing (JCIH)
updated the list of risk factors associated with permanent
congenital, delayed onset, or progressive hearing loss in
childhood [21]. Due to the overlap between congenital/neo-
natal and delayed onset risk factors, the JCIH presented a
single list. The JCIH recommends that all infants with these
risk factors be closely monitored for hearing loss. The com-
mittee proposed a comprehensive diagnostic assessment in
the neonatal period following a positive screening result
and appropriate surveillance after a negative screening re-
sult. The JCIH list is widely adopted in a large number of
UNHS programs, sometimes with adaptations. However,
this list was published more than 10 years ago. Based on
the evolution of care and new scientific knowledge during
recent years, updating the risk factors to reflect current
clinical practice is warranted [16]. Our systematic review
aims to identify the most up-to-date risk factors for hearing
loss in children and will include an examination of factors
by the onset of hearing loss.
Methods
Objectives and research questions
The overall aim of this systematic review is to synthesize
evidence on risk factors related to neonatal, early, and
late onset hearing loss as well as progressive hearing loss
in children. We will investigate all risk factors that have
an immediate or delayed effect on hearing. The resulting
information will inform surveillance protocols and will
be applicable to EHDI programs worldwide.
The review aims to answer the following primary re-
search question: what risk factors are associated with
permanent hearing loss in children? Risk factors related
to congenital, early, and late onset hearing loss will be
examined.
A secondary objective of this review is to investigate the
risk factors associated with progressive hearing loss in
children with congenital, early, or late onset hearing loss.
Design
This systematic review protocol has been developed ac-
cording to the Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols (PRISMA-P) (see
Additional file 1). We have registered the protocol in
the International Prospective Register of Systematic Re-
views (PROSPERO), registration number CRD420181
04121) [26].
Eligibility criteria
Primary research that meets the following criteria will be
included in the systematic review.
Study designs
It is anticipated that literature in this field will consist
largely of observational and descriptive studies. However,
some risk factors are related to medical conditions or treat-
ments and may be investigated through intervention stud-
ies. In an effort to collect the most comprehensive data, the
following study designs will be included: randomized con-
trolled trials, quasi-experimental studies, nonrandomized
comparative studies (prospective, or retrospective cohort,
case-control), nonrandomized studies without comparison
group (e.g., prospective or retrospective cohort, cross-
sectional), and case series. Consequently, we will exclude
from this review case reports/case studies (less than five
cases). Since we anticipate a very large number of articles,
we have essentially extended the “case study” to include < 5
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cases as we judged that these small cohorts would provide
little additional information. We will also exclude editorials,
viewpoints/opinion, literature reviews, conference abstracts,
guidelines, recommendations, consensus papers, qualitative
research, and gray literature, such as reports, thesis, and
notes.
Studies not directly related to the review questions but
that present pertinent information about the relation-
ships between risk factors and hearing loss will also be
included, as long as they meet the review inclusion cri-
teria (e.g., population, exposure, outcomes).
Population
All children with permanent bilateral or unilateral hearing
loss will be included. For this review, a child is defined as
age birth to 18 years. In most healthcare systems, pediatric
care targets children from birth to adolescence (defined as
less than 19 years), which is concordant with the Medical
Subject Heading (MeSH) definition (https://www.ncbi.
nlm.nih.gov/mesh/). The age limit is because only the
childhood onset of hearing loss is targeted by the research
question. We will include articles on children and adults
only if results are presented separately for children; we will
accept an upper range of the study group of approximately
age 21 years (young adults), when the majority of partici-
pants are children.
Exposure
Studies must report data on risk factors associated with
permanent hearing loss. Examples of specific risk factors
are congenital cytomegalovirus (cCMV), toxoplasmosis,
admission to a neonatal intensive care unit, ototoxic
medications, and a family history of hearing loss [21].
Risk factors may be present at birth (e.g, cCMV, family
history) or can present later in infancy or childhood
(e.g., hyperbilirubinemia, meningitis). Hearing loss asso-
ciated with these risk factors may have congenital onset,
late onset, or be progressive in nature.
Risk factors associated with temporary conductive
hearing loss will be excluded. Articles reporting “infants
at risk” will not be eligible; the specific risk factor(s)
must be identified.
Comparators
For studies that include a comparison group, the com-
parator will be either (1) no risk factors or (2) a com-
parison between one risk factor and other factors. Due
to the nature of studies in this field, it is anticipated that
most studies will not include a comparison group.
Outcome
Primary outcome The primary outcome is permanent
bilateral or unilateral hearing loss in childhood.
Permanent hearing loss refers to sensorineural hearing
loss or conductive loss that is structural in nature and
expected to last for 6 months or more [24]. Therefore,
studies reporting outcomes as sensorineural hearing loss,
auditory neuropathy spectrum disorder, permanent con-
ductive hearing loss or mixed loss will be included. Defi-
nitions of hearing loss (i.e., the severity of hearing loss)
will be accepted as defined by authors. Our interest in
this review is only on peripheral hearing loss; therefore,
studies reporting auditory processing disorders (or cen-
tral auditory processing) will be excluded.
We will categorize the outcomes according to the on-
set of hearing loss:
i) Congenital and early onset is defined as hearing loss
present at birth or diagnosed within the first 3
months of life. This definition is consistent with the
JCIH (2007) benchmark of diagnosis by 3 months of
age [21].
ii) Late onset is defined as the occurrence of hearing
loss, typically after 3 months of age, after a normal
hearing screen or confirmation of normal hearing
through audiologic assessment.
The flexibility in these definitions allows for known vari-
ations in the classification of onset of hearing loss in the
literature. Studies that report exclusively on temporary
conductive hearing loss or change in hearing following
surgical procedures (e.g., middle ear surgery, cochlear im-
plants) are not targeted by this review.
The diagnosis of hearing loss must be confirmed by
appropriate assessment methods at the time of the study.
Results from automated tests used for hearing screening
(such as automated otoacoustic emissions or automated
auditory brainstem responses) will be excluded. Out-
comes based solely on parental report of hearing loss
will also be excluded. Hearing loss defined as “requiring
hearing aids/amplification” will be accepted as a per-
manent hearing loss only if assessed by audiologists or
specialized professionals, based on appropriate tests.
Secondary outcome The secondary outcome of interest
for this review is progressive hearing loss. Any amount
of progressive hearing loss as defined by the authors will
be included. All other inclusion criteria detailed under
the primary outcome will apply.
Search method and information sources
The search strategy was developed in collaboration with a
health sciences librarian experienced in systematic re-
views. The following databases will be searched: MED-
LINE including Epub Ahead of Print, In-Process & Other
Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R) (1946 to July 30 2018), and Embase
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(1946 to July 30 2018) using the Ovid interface. CINAHL
will be searched from inception on July 23, 2018 (database
coverage dates not stated). Searches will be limited to the
cohort, case control, or randomized controlled trials using
existing filters. We will consider exposure of all risk fac-
tors outlined in the provincial surveillance protocol for
the Ontario IHP [24]. We will also include general
terms such as surveillance, risk factor, or risk indica-
tor to capture risk factors that may not be included
on the Ontario IHP list. The search strategy is pre-
sented in Additional file 2.
Restrictions will apply to language and publication date.
We will consider papers published only in English since
1990, that include birth cohorts ≥ 1985. Articles in other
languages will be screened only at the broad screening
level. The date limit was set to correspond broadly with
the implementation of UNHS programs.
Selection process and data management
The study selection involves three stages, managed within
covidence (covidence systematic review software, http://
www.covidence.org). Prior to the title and abstract screen-
ing, a screening form will be developed based on the in-
clusion and exclusion criteria and will be tested among
reviewers with a subset of articles. Titles and abstracts will
be assessed by two independent reviewers (BV and EF or
DN) for potential relevance; the reviewers will resolve any
conflicts (e.g., one reviewer selected “yes” or “maybe” and
the other selected “no”) and involve a third reviewer if re-
quired. At the second stage, two independent reviewers
(BV and EF or DN) will screen all potentially relevant full-
text articles (all articles tagged as “yes” or “maybe” during
the previous stage). Disagreements will be resolved by
consensus or a third member of the research team.
All processes will ensure that bias is minimized when
deciding whether to include or exclude certain studies,
based on the application of objective inclusion/exclusion
criteria, independent reviewers, and conflicts resolved
through a third reviewer.
A PRISMA flow chart will present the number of stud-
ies included/excluded in each stage of the selection
process. Main reasons for exclusion during the full-text
screening stage will be documented.
Data extraction
Using study-specific data forms, pre-determined data will
be extracted for each study. Data extracted will include:
1) Study characteristics (author names and contact
information, year, institution, country, language,
and source of funding)
2) Study design
3) Population characteristics (e.g., sample size, age at
diagnosis, degree of hearing loss, and permanent
bilateral/unilateral loss)
4) Details of control or comparison groups (if available
according to the study design)
5) Type of assessment
6) Exposure—risk factors (including any author-
specific definitions)
7) Onset of hearing loss (e.g., proportion with
congenital, early, late onset including author-
specific definitions)
8) Progressive loss (including author-specific
definitions)
9) Outcome data (including author-specific definitions
of hearing loss)
One researcher will extract all information, which will
be verified by a second reviewer. Discrepant findings will
be resolved through consensus or a third reviewer when
required.
Quality assessment
The risk of bias assessment will be conducted by one
researcher and verified by a second. Randomized con-
trol trials (RCT) will be evaluated using the Cochrane
Risk of Bias Tool (https://methods.cochrane.org/bias/
resources/cochrane-risk-bias-tool). Other study designs
will be assessed using the Qualitative Assessment Tool
for Quantitative Studies (Effective Public Health Prac-
tice Project, https://merst.ca/ephpp/). This tool, devel-
oped at McMaster University, provides an overall
methodological rating (weak, moderate, or strong)
based on an appraisal of eight domains: selection bias,
study design, confounders, blinding, data collection
methods, withdrawals and dropouts, intervention integ-
rity, and analysis.
Evidence synthesis
Study characteristics will be summarized narratively in
summary tables in the report; data will be presented as
frequencies and percentages, means and standard devi-
ations, or medians and interquartile ranges, as appro-
priate. It is anticipated that a full meta-analysis will not
be possible due to heterogeneity in research designs
and variability in study and reporting methods. A nar-
rative synthesis of the evidence will be conducted when
quantitative pooling of data is not possible. We antici-
pate that results will be organized in tables according
to individual risk factors (e.g., type or onset of risk fac-
tors, onset of hearing loss). Other classifications to be
considered are the types of hearing loss (e.g., sensori-
neural, auditory neuropathy spectrum disorder, mixed
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and permanent conductive disorders) and age of onset
(preschool versus school age).
The feasibility of meta-analysis will be determined
based on the similarity of clinical population, same risk
factors, type of outcomes, and study designs. If meta-
analysis is possible for some outcomes, we will use a
random effects model to aggregate results. For continu-
ous data, we will compute mean or standardized mean
differences with 95% confidence intervals (CIs). For di-
chotomous data, risk ratios with 95% CIs will be com-
puted, where appropriate. Statistical heterogeneity will
be evaluated using I2 statistics; for the interpretation of
I2, a rough guide of low (0–25%), moderate (25–50%),
substantial (50–75%), and considerable (75–100%) het-
erogeneity will be used [27]; potential reasons for het-
erogeneity will be explored. If there is considerable
heterogeneity, (> 75%), we will not conduct a pooled
analysis. If data permit, sensitivity analyses will be
undertaken with respect to risk of bias; assessing of low
risk of bias will be compared against high risk/unclear
risk of bias, funnel plots will be generated to assess for
publication bias if sufficient numbers of studies are
available for meta-analysis [27].
Subgroup analyses
We will examine the following variables in subgroup
analyses. Subgroups will be specific to age at onset (con-
genital and early infancy vs later childhood) and to spe-
cific conditions or treatments such as cCMV infection,
meningitis, and pediatric cancers treated with ototoxic
medication.
Quality of evidence
After data extraction and analysis, we will assess the qual-
ity and strength of the overall body of evidence using the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) tool (http://www.gradewor-
kinggroup.org) [28]. To use GRADE, a summary of find-
ings tables will be created. We will rate the evidence for
both the primary outcome (presence of bilateral or unilat-
eral hearing loss) and for the secondary outcome of pro-
gressive hearing loss. These outcomes will be assessed
across the five domains included in GRADE: risk of bias,
consistency, directness, precision, and publication bias.
Based on these assessments, we will rate the quality of the
evidence as high (very confident that the outcome is re-
lated to the risk factor), moderate (moderately confident
that outcome is related to risk factor), or low (limited con-
fidence in the outcome/risk factor association), or very
low (little confidence in the outcome/risk factor associ-
ation). Consensus will be reached by the research team
comprised of researchers and clinicians, and the quality of
evidence will guide the strength of the recommendations.
Discussion
The primary objective of this review is to collect and
synthesize information on risk factors associated with
congenital, early, or late onset permanent hearing loss
in children. It is widely acknowledged that children
with congenital or neonatal risk factors need to be
tested during the neonatal period and be closely moni-
tored for late onset hearing loss. Our question is of im-
portance because most newborn hearing screening and
surveillance programs are based on the 2007 JCIH fac-
tors. This list was released more than 10 years ago, and
its development process was not as accurate and trans-
parent as in a systematic review. In addition, this list is
modified in several programs suggesting that it does
not apply to their context or practice or it is not
followed in its entirety [29–32].
We intentionally developed a search strategy and
included numerous study designs to capture as many
risk factors as possible. Based on other reviews, it is
expected that the majority of studies will be descrip-
tive and include small samples or cohorts of children
with hearing loss. Our aim is to provide recommen-
dations for policy makers and clinics based on the
best available evidence. Consequently, limiting this re-
view to high-quality methodological designs such as
randomized controlled trials or large cohorts would
limit the evidence for decision-making. Because it is
intended to gather evidence for clinical practitioners
and policymakers, we are convinced that all types of
data are useful, on the condition that their methodo-
logical strengths and weaknesses are assessed, and in-
tegrated into the results.
The selection of publication date for inclusion in
this systematic review was a balanced decision. It has
to be long enough to include well-known risk factors
that have not been widely investigated recently, such
as congenital rubella syndrome. On the other hand, it
has to integrate the latest knowledge due to the evo-
lution of healthcare and treatments over time. For ex-
ample, care for premature newborns in neonatal
intensive care units has changed and practice in the
administration of ototoxic drugs is better controlled,
which has a positive impact on acquired hearing loss.
Consequently, the systematic review aims to integrate
both knowledge that has not been recently investi-
gated and new scientific data on the possible associ-
ation between risk factors and hearing loss. Only risk
factors included in the review articles will be ad-
dressed, that is, risk factors not included in articles
covered by our comprehensive search strategy will
not be considered for hearing loss in children.
We anticipate that the results from this systematic review
will guide decision-making in the Ontario IHP and will be
applicable to UNHS programs worldwide.
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